Entrada Therapeutics (TRDA) Total Liabilities (2020 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Total Liabilities of $64.7 million for Q1 2026, down 6.58% year-over-year from $69.2 million in Q1 2025, and down 9.24% quarter-over-quarter from $71.2 million in Q4 2025.
Entrada Therapeutics (TRDA) Total Liabilities (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Total Liabilities history runs 7 years deep, the most recent figure standing at $64.7 million for Q1 2026.
- In Q1 2026, Total Liabilities fell 6.58% year-over-year to $64.7 million; the TTM figure through Mar 2026 stood at $64.7 million (down 6.58% YoY), while the FY2025 annual figure was $71.2 million, down 27.04% from the prior year.
- Total Liabilities for Q1 2026 stood at $64.7 million, down from $71.2 million in the prior quarter.
- The five-year high for Total Liabilities was $287.1 million in Q2 2023, with the low at $39.3 million in Q1 2022.
- The 5-year median for Total Liabilities is $72.2 million (2025), against an average of $125.2 million.
- The sharpest annual moves came in 2023 and 2025: Total Liabilities surged 619.88% in 2023, then plunged 71.34% in 2025.
- Entrada Therapeutics' Total Liabilities stood at $39.5 million in 2022, then jumped by 474.23% to $226.8 million in 2023, then slumped by 56.95% to $97.6 million in 2024, then declined by 27.04% to $71.2 million in 2025, then retreated by 9.24% to $64.7 million in 2026.
- Business Quant data shows TRDA's Total Liabilities at $64.7 million in Q1 2026, $71.2 million in Q4 2025, and $72.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - | 65.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 65.47 Mn |
| Mar 31, 2026 | 64.66 Mn |
| Dec 31, 2025 | 71.25 Mn |
| Sep 30, 2025 | 72.18 Mn |
| Jun 30, 2025 | 69.28 Mn |
| Mar 31, 2025 | 69.22 Mn |
| Dec 31, 2024 | 97.64 Mn |
| Sep 30, 2024 | 132.14 Mn |
| Jun 30, 2024 | 152.04 Mn |
| Mar 31, 2024 | 241.48 Mn |
| Dec 31, 2023 | 226.83 Mn |
| Sep 30, 2023 | 238.37 Mn |
| Jun 30, 2023 | 287.08 Mn |
| Mar 31, 2023 | 245.96 Mn |
| Dec 31, 2022 | 39.50 Mn |
| Sep 30, 2022 | 41.24 Mn |
| Jun 30, 2022 | 39.88 Mn |
| Mar 31, 2022 | 39.31 Mn |
| Dec 31, 2021 | 7.12 Mn |
| Sep 30, 2021 | 7.50 Mn |